We are live on ! Find out more
NVS icon

Novartis

904 hedge funds and large institutions have $18.3B invested in Novartis in 2016 Q4 according to their latest regulatory filings, with 121 funds opening new positions, 302 increasing their positions, 354 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more first-time investments, than exits

New positions opened: 121 | Existing positions closed: 80

21% more call options, than puts

Call options by funds: $98.8M | Put options by funds: $81.4M

3% more funds holding

Funds holding: 877904 (+27)

0.62% more ownership

Funds ownership: 10.03%10.65% (+0.62%)

2% less capital invested

Capital invested by funds: $18.7B → $18.3B (-$411M)

15% less repeat investments, than reductions

Existing positions increased: 302 | Existing positions reduced: 354

25% less funds holding in top 10

Funds holding in top 10: 2821 (-7)

Holders
904
Holders Change
+27
Holders Change %
+3.08%
% of All Funds
22.6%
Holding in Top 10
21
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-25%
% of All Funds
0.53%
New
121
Increased
302
Reduced
354
Closed
80
Calls
$98.8M
Puts
$81.4M
Net Calls
+$17.4M
Net Calls Change
+$12.4M
Name Holding Trade Value Shares
Change
Change in
Stake
ClearBridge Investments
26
ClearBridge Investments
New York
$137M -$4.61M -71,101 -3%
Morgan Stanley
27
Morgan Stanley
New York
$132M -$1.96M -30,189 -1%
FWIA
28
Fort Washington Investment Advisors
Ohio
$119M +$13.6M +209,581 +13%
RJA
29
Raymond James & Associates
Florida
$114M +$48.1M +741,160 +73%
Boston Partners
30
Boston Partners
Massachusetts
$113M -$16.9M -259,980 -13%
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$110M +$22.3M +344,175 +26%
Fayez Sarofim & Co
32
Fayez Sarofim & Co
Texas
$109M -$4.42M -68,138 -4%
Capital International Investors
33
Capital International Investors
California
$107M
Capital World Investors
34
Capital World Investors
California
$104M -$36.2M -558,342 -26%
Ameriprise
35
Ameriprise
Minnesota
$102M -$2.62M -40,450 -3%
CAM
36
CGOV Asset Management
Ontario, Canada
$95.1M +$12.6M +195,003 +22%
PPA
37
Parametric Portfolio Associates
Washington
$94.3M +$9.38M +144,535 +11%
Dimensional Fund Advisors
38
Dimensional Fund Advisors
Texas
$88M -$774K -11,925 -0.9%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$83.3M -$1.45M -22,419 -2%
USSCPF
40
United States Steel & Carnegie Pension Fund
New York
$82.2M
RFS
41
Rockefeller Financial Services
New York
$78.2M -$551K -8,496 -0.7%
SCM
42
Sterling Capital Management
North Carolina
$78M +$295K +4,545 +0.4%
SI
43
Scharf Investments
California
$75.4M -$3.8M -58,539 -5%
SEI Investments
44
SEI Investments
Pennsylvania
$74.9M +$6.75M +104,059 +10%
EAM
45
Edge Asset Management
Washington
$74.6M +$14.3M +219,693 +24%
Goldman Sachs
46
Goldman Sachs
New York
$74.5M +$3.52M +54,310 +5%
Macquarie Group
47
Macquarie Group
Australia
$71.4M -$34M -524,273 -32%
Natixis Advisors
48
Natixis Advisors
Massachusetts
$69.2M -$4.29M -66,059 -6%
Fidelity Investments
49
Fidelity Investments
Massachusetts
$61.2M -$12.2M -187,948 -17%
JWBC
50
John W. Bristol & Co
New York
$61.1M -$2.16M -33,269 -3%

NVS Hedge Fund Activity: Q4 2016 in Review

904 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2016, worth a combined $18.3B — down 2.2% from $18.7B a quarter earlier.

Buyers outnumbered sellers: 121 funds opened new NVS positions and 80 closed out — a net gain of 41 holders — while 302 added to existing stakes and 354 trimmed.

The largest buyer was 1832 Asset Management, adding an estimated $213M. The largest seller was Cambiar Investors, exiting entirely with an estimated $176M sold.

  • 904 institutional investors held Novartis (NVS) as of Q4 2016, up from 877 in Q3 2016.
  • Funds reported $18.3B of Novartis stock for Q4 2016, down 2.2% quarter-over-quarter.
  • 121 funds opened new Novartis positions in Q4 2016 and 80 closed out, a net change of +41 holders.
  • The largest Novartis buyer in Q4 2016 was 1832 Asset Management, an estimated $213M added.
  • The largest Novartis seller in Q4 2016 was Cambiar Investors, an estimated $176M sold.

Based on aggregated 13F filings for Q4 2016.